Suraj Kalia
Stock Analyst at Oppenheimer
(3.69)
# 712
Out of 5,179 analysts
91
Total ratings
43.59%
Success rate
9.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $26.36 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $99.05 | +76.68% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $208.22 | +44.08% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $28.88 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $103.99 | +26.94% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $69.17 | +44.57% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $50.13 | +249.09% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $10.73 | +67.75% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $79.34 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $20.57 | +6.95% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $118.10 | +1.61% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $35.29 | -9.32% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $106.62 | -12.77% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.85 | +159.74% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $2.82 | +360.99% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $85.33 | +58.21% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $220.47 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $26.34 | +13.92% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.72 | +27,589.33% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $69.23 | +40.11% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $18.59 | +50.62% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.92 | +14.80% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.68 | +2,268.27% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $452.66 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.21 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $15.97 | +526.17% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $62.25 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $26.36
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $99.05
Upside: +76.68%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $208.22
Upside: +44.08%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $28.88
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $103.99
Upside: +26.94%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $69.17
Upside: +44.57%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $50.13
Upside: +249.09%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $10.73
Upside: +67.75%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $79.34
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $20.57
Upside: +6.95%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $118.10
Upside: +1.61%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $35.29
Upside: -9.32%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $106.62
Upside: -12.77%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $3.85
Upside: +159.74%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $2.82
Upside: +360.99%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $85.33
Upside: +58.21%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $220.47
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $26.34
Upside: +13.92%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.72
Upside: +27,589.33%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $69.23
Upside: +40.11%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $18.59
Upside: +50.62%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.92
Upside: +14.80%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $0.68
Upside: +2,268.27%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $452.66
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.21
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $15.97
Upside: +526.17%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $62.25
Upside: -